PG
CRL icon

Pendal Group’s Charles River Laboratories CRL Stock Holding History

Pendal Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,100
Closed -$319K – 559
2021
Q1 		$319K Hold
1,100
– – ﹤0.01% 478
2020
Q4 		$275K Buy
+1,100
New +$262K ﹤0.01% 448

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Pendal Group's CRL Position: Q2 2021 in Review

Pendal Group sold out of Charles River Laboratories (CRL) in Q2 2021, closing a stake of 1,100 shares — an estimated $319K sold.

Pendal Group first reported a position in CRL in Q4 2020 and held it in 2 quarters. The position peaked at $319K in Q1 2021. 638 funds tracked by Wall St. Rank hold CRL as of Q2 2021.

  • Pendal Group reported no remaining Charles River Laboratories position as of Q2 2021 after selling out during the quarter.
  • Pendal Group sold 1,100 Charles River Laboratories shares in Q2 2021, an estimated $319K.
  • Pendal Group first reported a position in Charles River Laboratories in Q4 2020 and held it in 2 quarters.
  • Pendal Group's Charles River Laboratories position peaked at $319K in Q1 2021.
  • 638 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2021.

Based on Pendal Group's 13F filing for Q2 2021, filed 28 Jul 2021.